SOURCE: InoLife Technologies Inc.
Company Will Feature and Inform Medical Professionals on the Advantages and Availability of the DNA-Based Plavix Metabolizing Test
RALEIGH, NC–(Marketwire – November 30, 2010) – InoLife Technologies, Inc. (
“This convention provides an excellent opportunity for our Company to expose our products to the medical community as well as the industry press,” stated Gary Berthold, CEO of InoLife Technologies, Inc. “We at InoLife Technologies would like to invite those health-care professionals that are attending the convention to visit booth 240 to discuss opportunities and for demonstrations of the Company’s DNA-based testing products.”
InoLife will take advantage of this forum to educate physicians and healthcare practitioners on the advantages and availability of the Company’s Plavix metabolizing test. This DNA-based testing procedure can identify how a patient’s genetic inheritance may affect the body’s response to the popular drug commonly used for patients with cardiovascular risks.
The A4M expects approximately 3000 professionals to attend the convention. It is billed to be the largest and most influential conference and expo worldwide on preventative medicine and bio-medical technologies. The A4M organization is comprised of 22,000-plus members that include physicians, health practitioners, scientists, government officials and members of the general public representing over 105 nations. Eighty-five percent (85%) of the organization’s members are physicians (MD, DO,MBBS) followed by 12% that consists of scientists, researchers, and health practitioners, leaving 3% that are government officials, members of the working press and the general public.
The A4M is dedicated to educating physicians, scientists and health practitioners on biomedical sciences, breaking technologies and anti aging issues. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.
About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.
The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.